Cardiome Reports Trial Results

Shares of Cardiome Pharma Corp. (CRME) tumbled $1.51 to close at $11.80 after announcing that a mid-stage clinical trial of the company's irregular heartbeat medication indicated that a lower 300 mg dose was more effective than a 600 mg dose.